Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.

1 Blasi F, Dara M, van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013; 41: 491–494. 2 Blasi F, Barnes PJ, Gaga M, et al. Future directions for the ERS: Presidential plans. Eur Respir J 2013; 42: 875–880. 3 World Health Organization. Global Tuberculosis Report 2012. Geneva, WHO Press, 2012. Available from: www. who.int/tb/publications/global_report/gtbr12_main.pdf. 4 Migliori GB, Dara M, de Colombani P, et al. Multidrug-resistant tuberculosis in Eastern Europe: still on the increase? Eur Respir J 2012; 39: 1290–1291. 5 Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425–1431. 6 Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156–168. 7 Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169–179. 8 Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143–151. 9 Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516–528. 10 Migliori GB, Zellweger JP, Abubakar I, et al. European Union standards for tuberculosis care. Eur Respir J 2012; 39: 807–819.